These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 8791271)
1. Prognostic value of serum analyses of S-100 beta protein in malignant melanoma. von Schoultz E; Hansson LO; Djureen E; Hansson J; Kärnell R; Nilsson B; Stigbrand T; Ringborg U Melanoma Res; 1996 Apr; 6(2):133-7. PubMed ID: 8791271 [TBL] [Abstract][Full Text] [Related]
2. Clinical and prognostic relevance of serum S-100 beta protein in malignant melanoma. Schultz ES; Diepgen TL; Von Den Driesch P Br J Dermatol; 1998 Mar; 138(3):426-30. PubMed ID: 9580794 [TBL] [Abstract][Full Text] [Related]
3. Prognostic value of serum analyses of S-100 protein beta in malignant melanoma. Hansson LO; von Schoultz E; Djureen E; Hansson J; Nilsson B; Ringborg U Anticancer Res; 1997; 17(4B):3071-3. PubMed ID: 9329604 [TBL] [Abstract][Full Text] [Related]
4. S100B protein, 5-S-cysteinyldopa and 6-hydroxy-5-methoxyindole-2-carboxylic acid as biochemical markers for survival prognosis in patients with malignant melanoma. Kärnell R; von Schoultz E; Hansson LO; Nilsson B; Arstrand K; Kågedal B Melanoma Res; 1997 Oct; 7(5):393-9. PubMed ID: 9429222 [TBL] [Abstract][Full Text] [Related]
5. Serum S-100 protein: a potentially useful prognostic marker in cutaneous melanoma. Abraha HD; Fuller LC; Du Vivier AW; Higgins EM; Sherwood RA Br J Dermatol; 1997 Sep; 137(3):381-5. PubMed ID: 9349333 [TBL] [Abstract][Full Text] [Related]
6. Serum S-100b protein as a prognostic marker in malignant cutaneous melanoma. Mårtenson ED; Hansson LO; Nilsson B; von Schoultz E; Månsson Brahme E; Ringborg U; Hansson J J Clin Oncol; 2001 Feb; 19(3):824-31. PubMed ID: 11157036 [TBL] [Abstract][Full Text] [Related]
7. Melanoma progression and serum L-dopa/L-tyrosine ratio: a comparison with S100B. Stoitchkov K; Letellier S; Garnier JP; Bousquet B; Tsankov N; Morel P; Ghanem G; Le Bricon T Melanoma Res; 2002 Jun; 12(3):255-62. PubMed ID: 12140382 [TBL] [Abstract][Full Text] [Related]
8. Comparative study of YKL-40, S-100B and LDH as monitoring tools for Stage IV melanoma. Egberts F; Kotthoff EM; Gerdes S; Egberts JH; Weichenthal M; Hauschild A Eur J Cancer; 2012 Mar; 48(5):695-702. PubMed ID: 21917447 [TBL] [Abstract][Full Text] [Related]
9. Heterogenous S-100B protein expression patterns in malignant melanoma and association with serum protein levels. Bánfalvi T; Udvarhelyi N; Orosz Z; Gergye M; Gilde K; Tímár J Oncology; 2003; 64(4):374-9. PubMed ID: 12759535 [TBL] [Abstract][Full Text] [Related]
10. Comparison of prognostic significance of serum 5-S-Cysteinyldopa, LDH and S-100B protein in Stage III-IV malignant melanoma. Bánfalvi T; Boldizsár M; Gergye M; Gilde K; Kremmer T; Ottó S Pathol Oncol Res; 2002; 8(3):183-7. PubMed ID: 12515998 [TBL] [Abstract][Full Text] [Related]
11. S100 protein serum levels in cutaneous malignant melanoma. Seregni E; Massaron S; Martinetti A; Illeni MT; Rovini D; Belli F; Agresti R; Greco M; Cascinelli N; Bombardieri E Oncol Rep; 1998; 5(3):601-4. PubMed ID: 9538159 [TBL] [Abstract][Full Text] [Related]
12. Monitoring malignant melanoma with the S-100B tumour marker. Bonfrer JM; Korse CM Recent Results Cancer Res; 2001; 158():149-57. PubMed ID: 11092042 [TBL] [Abstract][Full Text] [Related]
13. Comparison of S100 protein and MIA protein as serum marker for malignant melanoma. Djukanovic D; Hofmann U; Sucker A; Rittgen W; Schadendorf D Anticancer Res; 2000; 20(3B):2203-7. PubMed ID: 10928178 [TBL] [Abstract][Full Text] [Related]
14. Prognostic implications of protein S-100beta serum levels in the clinical outcome of high-risk melanoma patients. Domingo-Domènech J; Castel T; Auge JM; Garcia-Albeniz XA; Conill C; Puig S; Vilella R; Matas J; Malvehy J; Gascón P; Mellado B; Molina R Tumour Biol; 2007; 28(5):264-72. PubMed ID: 17962723 [TBL] [Abstract][Full Text] [Related]
15. Prognostic value of serum S-100B in malignant melanoma. Andrés R; Mayordomo JI; Zaballos P; Rodino J; Isla D; Escudero P; Elosegui L; Filipovich E; Saenz A; Polo E; Tres A Tumori; 2004; 90(6):607-10. PubMed ID: 15762365 [TBL] [Abstract][Full Text] [Related]
16. Predictive value of serum S100B for monitoring patients with metastatic melanoma during chemotherapy and/or immunotherapy. Hauschild A; Engel G; Brenner W; Gläser R; Mönig H; Henze E; Christophers E Br J Dermatol; 1999 Jun; 140(6):1065-71. PubMed ID: 10354072 [TBL] [Abstract][Full Text] [Related]
17. The value of pre operative S-100B and SUV in clinically stage III melanoma patients undergoing therapeutic lymph node dissection. Kruijff S; Bastiaannet E; Speijers MJ; Kobold AC; Brouwers AH; Hoekstra HJ Eur J Surg Oncol; 2011 Mar; 37(3):225-32. PubMed ID: 21277729 [TBL] [Abstract][Full Text] [Related]
18. Clinical use of p-proteasome in discriminating metastatic melanoma patients: comparative study with LDH, MIA and S100B protein. Henry L; Fabre C; Guiraud I; Bastide S; Fabbro-Peray P; Martinez J; Lavabre-Bertrand T; Meunier L; Stoebner PE Int J Cancer; 2013 Jul; 133(1):142-8. PubMed ID: 23238767 [TBL] [Abstract][Full Text] [Related]
19. Use of serum 5-S-CD and S-100B protein levels to monitor the clinical course of malignant melanoma. Bánfalvi T; Gilde K; Gergye M; Boldizsár M; Kremmer T; Ottó S Eur J Cancer; 2003 Jan; 39(2):164-9. PubMed ID: 12509947 [TBL] [Abstract][Full Text] [Related]
20. Serum S100B is suitable for prediction and monitoring of response to chemoimmunotherapy in metastatic malignant melanoma. Hamberg AP; Korse CM; Bonfrer JM; de Gast GC Melanoma Res; 2003 Feb; 13(1):45-9. PubMed ID: 12569284 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]